HMG-CoA Inhibitors
PREGNANCY CATEGORY X
Therapeutic Actions
HMG-CoA inhibitors are antihyperlipidemic. They are a fungal metabolite that inhibits the enzyme that catalyzes the first step in the cholesterol synthesis pathway in humans, resulting in a decrease in serum cholesterol and serum LDLs (associated with increased risk of CAD); either an increase or no change in serum HDLs (associated with decreased risk of CAD); and a decrease in triglycerides.
Indications
Adjunct to diet in the treatment of elevated total and LDL cholesterol in patients with primary hypercholesterolemia (types IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacologic measures has not been adequate
Primary prevention of coronary events (lovastatin, pravastatin)
Secondary prevention of CV events (fluvastatin, lovastatin, pravastatin, simvastatin)
Contraindications and Cautions
Contraindicated with allergy to HMG-CoA inhibitors, fungal byproducts, pregnancy, or lactation, concurrent gemfibrozil therapy.
Use cautiously with impaired hepatic function, cataracts.
Adverse Effects
CNS: Headache, blurred vision, dizziness, insomnia, fatigue, muscle cramps, cataracts
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
